Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
This study has been terminated.
(Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.)
Information provided by (Responsible Party):
First received: April 2, 2007
Last updated: May 12, 2017
Last verified: May 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been terminated.|
|Study Completion Date:||August 8, 2013|
|Primary Completion Date:||August 4, 2013 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Pujol JL, Vansteenkiste JF, De Pas TM, Atanackovic D, Reck M, Thomeer M, Douillard JY, Fasola G, Potter V, Taylor P, Bosquée L, Scheubel R, Jarnjak S, Debois M, de Sousa Alves P, Louahed J, Brichard VG, Lehmann FF. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol. 2015 Oct;10(10):1458-67. doi: 10.1097/JTO.0000000000000653.